MX2017009122A - Inhalador de polvo seco con propionato de fluticasona y xinafoato de salmeterol. - Google Patents

Inhalador de polvo seco con propionato de fluticasona y xinafoato de salmeterol.

Info

Publication number
MX2017009122A
MX2017009122A MX2017009122A MX2017009122A MX2017009122A MX 2017009122 A MX2017009122 A MX 2017009122A MX 2017009122 A MX2017009122 A MX 2017009122A MX 2017009122 A MX2017009122 A MX 2017009122A MX 2017009122 A MX2017009122 A MX 2017009122A
Authority
MX
Mexico
Prior art keywords
fluticasone propionate
dry powder
dose
salmeterol xinafoate
powder inhaler
Prior art date
Application number
MX2017009122A
Other languages
English (en)
Other versions
MX383344B (es
Inventor
Dalvi Mukul
Kee Tee Seah
Original Assignee
Teva Branded Pharmaceutical Products R&D Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55443303&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017009122(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Branded Pharmaceutical Products R&D Inc filed Critical Teva Branded Pharmaceutical Products R&D Inc
Publication of MX2017009122A publication Critical patent/MX2017009122A/es
Publication of MX383344B publication Critical patent/MX383344B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0005—Details of inhalators; Constructional features thereof with means for agitating the medicament
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0005—Details of inhalators; Constructional features thereof with means for agitating the medicament
    • A61M15/0006—Details of inhalators; Constructional features thereof with means for agitating the medicament using rotating means
    • A61M15/0008—Details of inhalators; Constructional features thereof with means for agitating the medicament using rotating means rotating by airflow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0021—Mouthpieces therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta invención proporciona un inhalador de polvo seco que comprende: un medicamento en polvo seco que comprende propionato de fluticasona, xinafoato de salmeterol y un portador lactosa; en el que la dosis suministrada de propionato de fluticasona por activación es inferior a 100 µg; y en el que la dosis proporciona un FEV1, ajustado a los datos de base de un paciente, de más de 150 mL dentro de los 30 minutos de haber recibido la dosis. Un método de tratamiento a un paciente incluye administrar a un paciente un medicamento en polvo seco que tiene propionato de fluticasona, xinafoato de salmeterol y un portador lactosa; en el que la dosis suministrada de propionato de fluticasona por activación es inferior a 100 pg; y en el que la dosis proporciona un FEV1, ajustado a los datos de base de un paciente, de más de 150 mL dentro de los 30 minutos de recibir la dosis.
MX2017009122A 2015-01-20 2016-01-20 Inhalador de polvo seco con propionato de fluticasona y xinafoato de salmeterol. MX383344B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562105479P 2015-01-20 2015-01-20
PCT/US2016/014072 WO2016118589A1 (en) 2015-01-20 2016-01-20 Dry powder inhaler comprising fluticasone propionate and salmeterol xinafoat

Publications (2)

Publication Number Publication Date
MX2017009122A true MX2017009122A (es) 2017-10-12
MX383344B MX383344B (es) 2025-03-13

Family

ID=55443303

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017009122A MX383344B (es) 2015-01-20 2016-01-20 Inhalador de polvo seco con propionato de fluticasona y xinafoato de salmeterol.
MX2021006751A MX2021006751A (es) 2015-01-20 2017-07-12 Inhalador de polvo seco con propionato de fluticasona y xinafoato de salmeterol.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021006751A MX2021006751A (es) 2015-01-20 2017-07-12 Inhalador de polvo seco con propionato de fluticasona y xinafoato de salmeterol.

Country Status (19)

Country Link
US (2) US20180015035A1 (es)
EP (1) EP3247331A1 (es)
JP (1) JP2018503687A (es)
KR (1) KR20170103975A (es)
CN (1) CN107530357A (es)
AR (1) AR104771A1 (es)
AU (2) AU2016209363B2 (es)
BR (1) BR112017015353A2 (es)
CA (1) CA2974125A1 (es)
CL (1) CL2017001859A1 (es)
CO (1) CO2017008395A2 (es)
EA (1) EA201791632A1 (es)
HK (1) HK1245125A1 (es)
IL (1) IL253499A0 (es)
MA (1) MA41378A (es)
MX (2) MX383344B (es)
PE (1) PE20171258A1 (es)
TW (1) TW201628607A (es)
WO (1) WO2016118589A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6543620B2 (ja) * 2013-10-07 2019-07-10 テバ ブランデッド ファーマシューティカル プロダクツ アール アンド ディー インコーポレイテッド ドライパウダー吸入器
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol
EA038928B1 (ru) 2016-11-18 2021-11-10 Нортон (Уотерфорд) Лимитед Устройство доставки лекарства с электроникой
CN110201281B (zh) * 2018-02-28 2021-08-06 张江 吸入给药装置和吸入给药组合结构
CN110201278B (zh) * 2018-02-28 2021-07-30 张江 用于吸入给药的药盒和吸入给药组合结构
CN110201280B (zh) * 2018-02-28 2021-07-30 张江 用于吸入给药装置的吸嘴和吸入给药装置
CN110064110A (zh) * 2019-05-29 2019-07-30 上海理工大学 一种容积旋钮式干粉储存吸入装置
GB2585206B (en) 2019-07-01 2021-08-11 Merxin Ltd Portable inhaler

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
AR028747A1 (es) * 2000-06-23 2003-05-21 Norton Health Care Ltd Desaglomerador para inhalador de polvo seco accionado por la respiracion, un inhalador de polvo seco y un metodo de desaglomeracion de polvo seco.
PE20020163A1 (es) * 2000-06-23 2002-03-04 Norton Healthcare Ltd Sistema presurizado de receptaculo para inhalador de medicamento
AR030516A1 (es) * 2000-08-31 2003-08-20 Glaxo Group Ltd Uso de una combinacion de salmeterol y fluticasona
EP2283818B1 (en) * 2000-11-30 2017-08-02 Vectura Limited Method of making particles for use in a pharmaceutical composition
GB0124523D0 (en) 2001-10-12 2001-12-05 Glaxo Group Ltd Pharmaceutical combination
WO2004030659A1 (en) 2002-09-30 2004-04-15 Acusphere, Inc. Sustained release porous microparticles for inhalation
US9114081B2 (en) * 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
MX337126B (es) * 2009-05-29 2016-02-12 Pearl Therapeutics Inc Administracion respiratoria de agentes activos.
WO2011035128A1 (en) * 2009-09-17 2011-03-24 Mutual Pharmaceutical Company, Inc. Method of treating asthma with antiviral agents
GB0919465D0 (en) 2009-11-06 2009-12-23 Norton Healthcare Ltd Airflow adaptor for a breath-actuated dry powder inhaler
KR101618421B1 (ko) * 2010-05-18 2016-05-04 아이박스 파마슈티컬즈 아일랜드 흡입기용 용량 계수기, 흡입기 및 그의 샤프트
EP2571486A4 (en) 2010-05-20 2013-12-04 Sun Pharma Advanced Res Co Ltd DRY POWDER INHALATION COMPOSITION
KR20130140358A (ko) * 2012-06-14 2013-12-24 한미약품 주식회사 살메테롤 지나포산염, 플루티카손 프로피오네이트 및 티오트로피움 브로마이드를 포함하는 흡입 제형용 건조 분말 및 이의 제조방법
CA2910697A1 (en) * 2013-04-29 2014-11-06 Sanofi Sa Inhalable pharmaceutical compositions and the inhaler devices containing them
EP2991965B1 (en) * 2013-05-03 2017-06-21 Dow Global Technologies LLC Process for equilibrium-limited reactions
JP6543620B2 (ja) * 2013-10-07 2019-07-10 テバ ブランデッド ファーマシューティカル プロダクツ アール アンド ディー インコーポレイテッド ドライパウダー吸入器
KR20170068571A (ko) * 2014-10-16 2017-06-19 테바 브랜디드 파마슈티컬 프로덕츠 알앤디, 인코포레이티드 건조 분말 제제
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol

Also Published As

Publication number Publication date
CO2017008395A2 (es) 2018-01-05
HK1245125A1 (zh) 2018-08-24
JP2018503687A (ja) 2018-02-08
AU2021202784A1 (en) 2021-05-27
AU2016209363A1 (en) 2017-08-24
WO2016118589A1 (en) 2016-07-28
AR104771A1 (es) 2017-08-16
CN107530357A (zh) 2018-01-02
IL253499A0 (en) 2017-09-28
EP3247331A1 (en) 2017-11-29
AU2016209363B2 (en) 2021-02-04
US20180015035A1 (en) 2018-01-18
PE20171258A1 (es) 2017-08-28
US9415008B2 (en) 2016-08-16
CA2974125A1 (en) 2016-07-28
US20160206559A1 (en) 2016-07-21
KR20170103975A (ko) 2017-09-13
BR112017015353A2 (en) 2018-01-16
MX383344B (es) 2025-03-13
TW201628607A (zh) 2016-08-16
CL2017001859A1 (es) 2018-04-06
MX2021006751A (es) 2021-07-15
MA41378A (fr) 2017-11-28
EA201791632A1 (ru) 2017-12-29

Similar Documents

Publication Publication Date Title
MX2016004316A (es) Inhalador de polvo seco.
MX2017009122A (es) Inhalador de polvo seco con propionato de fluticasona y xinafoato de salmeterol.
DOP2017000268A (es) Metodos y kits para tratar depresion
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
MX380767B (es) Métodos para reducir el riesgo cardiovascular.
ZA201808537B (en) Combination therapies
MX2017000627A (es) Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe).
BR112018010671A8 (pt) dispositivos e métodos de distribuição de fármaco com mudança de forma
CO2020008561A2 (es) Dosificación subcutánea de anticuerpos anti-cd38
BR112015019064A2 (pt) métodos de tratamento de melanoma
BR112017017448A2 (pt) métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho
MX2017000628A (es) Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia.
BR112015030377A2 (pt) preparação compreendendo pelo menos um quimioterápico ou substância citotóxica para uso no tratamento de uma doença de um paciente mamífero, preparação e método para tratamento de câncer em um paciente mamífero através de terapia de radiação
BR112016002574A8 (pt) composição de enzima digestiva, processo para a preparação da composição de enzima digestiva, e, método para o tratamento de um paciente adulto ou pediátrico com necessidade da composição de enzima digestiva
MX2018002000A (es) Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina.
BR112017023517A2 (pt) anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20
CO2016003340A2 (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
MX2018016332A (es) Quimioterapias de combinacion.
MX2020004497A (es) Administracion oral de analogos del peptido glp-1.
AR100369A1 (es) Composición de dosis fija de formoterol y budesonide
CO2020007129A2 (es) Tratamientos de combinación que comprenden la administración de 1h-pirazolo[4,3-b]piridinas
MX390751B (es) Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila.
EA201691562A2 (ru) Фильтры для инфузионных наборов
AR102903A1 (es) Inhalador de polvo seco
MX2022003628A (es) Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente.